ProBER
Financiado
Personalised Bioelectronics for Epithelial Repair
Care of chronic wounds constitutes an enormous socioeconomic burden to the European Healthcare system calling for new strategies to support healing for wounds at risk. As a restored epithelium will outperform any artificial scaffo...
Care of chronic wounds constitutes an enormous socioeconomic burden to the European Healthcare system calling for new strategies to support healing for wounds at risk. As a restored epithelium will outperform any artificial scaffold in protecting the underlying tissue, fast re-epithelialization is the primary goal. In culture models of wound healing, we have shown that direct current stimulation (DCs) makes epithelial ruptures close up to three times faster, and that the key to success is dosage. This aspect is overlooked in previous clinical studies. Typically, DCs thresholds established in cultures are lost in translation, because of the lack of technologies able to support DCs on the skin. In ProBER we will change this. We will exploit technologies for making conformal, metal free, biocompatible DCs electrodes for skin developed in the ERC StG SPEEDER. By focussing on personalisation of the bioelectronic wound dressing we will ensure that the same efficient parameter space established in culture models can be precisely replicated on actual wounds. Our goal is a fabrication pipeline with wound dressings tailored to the wound. We will collect information on wound size and shape using LIDAR 3D scanning, and feed this, as well as impedance measurements, to an automated personalisation algorithm. Personalisation extends beyond fabrication as the ProBER wound dressing will include integrated impedance sensors to ensure that DCs is adapted to the healing progress. In ProBER, we will prepare our promising concept for subsequent clinical studies, which requires a functional concept for fabrication and proof-of-concept demonstration. We will co-develop our wound dressing together with stakeholders in healthcare, and work to protect IP, recruit strategic partners and form alliances for clinical translation.
ver más
Duración del proyecto: 17 meses
Fecha Inicio: 2023-06-01
Fecha Fin: 2024-11-30
Fecha Fin: 2024-11-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-06-01
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2022-POC2:
ERC PROOF OF CONCEPT GRANTS2
Cerrada
hace 2 años
Líder del proyecto
CHALMERS TEKNISKA HOGSKOLA AB
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5